Non-Small Cell Lung Cancer Therapeutics Market to Reach USD 10.5 Billion by 2020

Non-Small Cell Lung Cancer Therapeutics Market to Reach USD 10.5 Billion by 2020

The global non-small cell lung cancer therapeutics market is estimated to reach USD 10.5 Billion in 2020, growing at a CAGR of 11.8% from 2016 to 2020, according to a new market research report Non-Small Cell Lung Cancer Therapeutics Market – Global NSCLC Drug Classes and Clinical Drugs Pipeline Analysis and Forecast 2016-2020, published by iHealthcareAnalyst, Inc.

Visit the Non-Small Cell Lung Cancer Therapeutics Market – Global NSCLC Drug Classes and Clinical Drugs Pipeline Analysis and Forecast 2016-2020 report at https://www.ihealthcareanalyst.com/report/non-small-cell-lung-cancer-therapeutics-market/

Non-small cell lung cancer is the most common type of lung cancer (about 85% of lung cancers) and it usually grows and spreads more slowly than small cell lung cancer. Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are all subtypes of non-small cell lung cancer. The global non-small cell lung cancer therapeutics market report estimates the market size (Revenue USD million – 2013 to 2020) for key market segments based on the drug classes (angiogenesis inhibitors – Avastin, Cyramza; epidermal growth factor receptor blockers – Tarceva, Gilotrif, Iressa; Folate antimetabolites – Alimta; kinase inhibitors – Xalkori, Zykadia; microtubule stabilizers – Abraxane, Docetaxel; and PD-1/ PD-L1 inhibitors – Opdivo, Keytruda), clinical pipeline analysis of phase 1, 2 and 3 drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib, etc.), and forecasts growth trends (CAGR% – 2016 to 2020). It also provides the detailed market landscape and profiles of major competitors in the global market including company overview, financial snapshot, major products and services offered, and recent trends.

The global non-small cell lung cancer therapeutics is segmented as:

  1. Drug Class
    • Angiogenesis Inhibitor
      • Avastin (Bevacizumab)
      • Cyramza (Ramucirumab)
    • Epidermal Growth Factor Receptor Blocker
      • Tarceva (Erlotinib)
      • Gilotrif (Afatinib)
      • Iressa (Gefitinib)
    • Folate Antimetabolites
      • Alimta (Pemetrexed)
    • Kinase Inhibitor
      • Xalkori (Crizotinib)
      • Zykadia (Ceritinib)
    • Microtubule Stabilizer
      • Abraxane (Paclitaxel Protein Bound)
      • Docetaxel
    • PD-1/ PD-L1 Inhibitor
      • Opdivo (Nivolumab)
      • Keytruda (Pembrolizumab)
  1. Pipeline Analysis (Phase 1, 2 and 3)
    • Avelumab
    • MPDL3280A
    • MEDI4736
    • Abemaciclib
    • Others
    • Pipeline Analysis (Phase 1 and 2)
  1. Geography (Region, Country)
    • North America (U.S., Canada)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World
  1. Company Profiles
    • AstraZeneca plc.
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene Corporation
    • Eli Lilly & Co.
    • Hoffmann-La Roche Ltd.
    • GlaxoSmithKline PLC
    • Pfizer, Inc.
    • Sun Pharmaceutical Industries Ltd.

About Us

iHealthcareAnalyst, Inc. is a global health care market research and consulting company providing market analysis, and competitive intelligence services to global clients. The Company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.

iHealthcareAnalyst, Inc. provides industry participants and stakeholders with strategically analyzed, unbiased view of market dynamics and business opportunities within its coverage areas.

Contact Us

iHealthcareAnalyst, Inc.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
United States
Email: [email protected]
Website: https://www.ihealthcareanalyst.com

2016-10-14T06:19:34+00:00 Categories: Press Releases|